相关实验视频
Updated: Jun 9, 2025

08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
15.7K
多种细胞死亡模式预测了黑色素瘤患者的预后和药物敏感性
Zewei Chen1,2, Ruopeng Zhang1,2, Zhoukai Zhao1,2
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Frontiers in pharmacology
|October 23, 2024
概括
一个新的细胞死亡指数 (CDI) 模型预测了黑色素瘤的预后和药物敏感性. 这种基于编程细胞死亡 (PCD) 基因的模型,可以识别出更糟糕的结果和治疗耐药性的患者.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 黑色素瘤治疗面临着当前模式的挑战.
- 需要更好的模型来预测黑色素瘤预后和药物敏感性.
- 编程细胞死亡 (PCD) 模式对瘤进展至关重要,可能是关键指标.
研究的目的:
- 开发和验证一种用于评估黑色素瘤预后和药物敏感性的新型模型.
- 研究13种编程细胞死亡 (PCD) 模式在黑色素瘤中的作用.
- 为临床应用建立细胞死亡指数 (CDI).
主要方法:
- 分析了13种PCD模式和相关基因.
- 使用机器学习算法构建了一个细胞死亡指数 (CDI).
- 使用TCGA-SKCM,GSE19234和GSE65904队列的转录组,基因组和临床数据验证了CDI模型.
主要成果:
- 建立了一个十基因签名CDI,将患者分为高CDI和低CDI组.
- 高CDI组显示出较少的免疫透细胞和对多塞塔克塞尔和阿克西提尼布的耐药性.
- 较高的CDI值与黑色素瘤患者的术后预后较差相关 (p < 0.01).
结论:
- CDI模型准确地预测了黑色素瘤的临床预后.
- CDI模型在预测黑色素瘤患者的药物敏感性方面表现出有效性.
- 这种多PCD模式模型为个性化黑色素瘤治疗提供了一个有前途的工具.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328

